Nestor Galvez-Jimenez MD is Professor of Medicine (Neurology-Florida) at Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, and Pauline M. Braathen Endowed Chair, Director of the Neurological Center, Chief of the Movement Disorders Unit, and Chairman of the Department of Neurology, at Cleveland Clinic Florida, Weston, FL, USA. Hubert H. Fernandez is Head of the Division of Movement Disorders at the Department of Neurology, Cleveland Clinic, Cleveland, OH, USA. Alberto J. Espay is Associate Professor of Neurology, Director, and Endowed Chair at the James J. and Joan A. Gardner Center for Parkinson's Disease and Movement Disorders, University of Cincinnati Academic Health Center, Cincinnati, OH, USA. Susan H. Fox is Associate Professor of Neurology at the University of Toronto, Associate Director of the Movement Disorders Clinic at Toronto Western Hospital, and Staff Neurologist in the Division of Neurology, Department of Medicine, University Health Network, Toronto, Canada.

• Part I. The Pharmacological Basis for Parkinson's Disease Treatment: 1. The pharmacological basis of Parkinson's disease therapy: an overview; 2. Anticholinergic agents in the management of Parkinson's disease; 3. Amantadine and antiglutamatergic drugs in the management of Parkinson's disease; 4. Monoamine oxidase inhibitors in the management of Parkinson's disease; 5. Oral dopamine agonists in the anagement of Parkinson's disease; 6. Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson's disease; 7. Oral and infusion levodopa therapy in the management of Parkinson's disease; 8. Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease; 9. Experimental pharmacological agents in the management of Parkinson's disease; Part II. Management of Non-Motor Symptoms of Parkinson's Disease: 10. Management of autonomic dysfunction in Parkinson's disease; 11. Management of cognitive impairment in Parkinson's disease; 12. A neurobehavioralist approach to the management of cognitive impairment in Parkinson's disease; 13. Management of disease-related behavioral disturbances in Parkinson's disease; 14. Management of treatment-related behavioral disturbances in Parkinson's disease; 15. Management of sleep disorders in Parkinson's disease; 16. Management of pain and euromuscular complications in Parkinson's disease; Part III. Surgical Management of Parkinson's Disease: 17. Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease; 18. Deep brain stimulation of the globus pallidus internus in the management of Parkinson's disease; 19. Deep brain stimulation of the subthalamic nucleus in the management of Parkinson's disease; 20. Deep brain stimulation of the thalamic ventral intermediate nucleus in the management of Parkinson's disease; 21. Emerging targets and other stimulation-related procedures in the management of Parkinson's disease; Part IV. Clinical Trials in Parkinson's Disease: Lessons, Controversies and Challenges: 22. Rating scales and clinical outcome measures in the evaluation of patients with Parkinson's disease; 23. Functional imaging markers as outcome measures in clinical trials for Parkinson's disease; 24. Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease; 25. Lessons learned: neuroprotective trials in Parkinson's disease; 26. Lessons learned: symptomatic trials in early Parkinson's disease; 27. Controversy: GPi vs STN deep brain stimulation in the management of Parkinson's disease; 28. Controversy: ablative surgery vs deep brain stimulation in the management of Parkinson's disease; 29. Controversy: mid-stage vs advanced stage deep brain stimulation in the management of Parkinson's disease; 30. Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease; 31. Lessons and challenges of trials for other non-motor complications of Parkinson's disease; 32. Lessons and challenges of trials involving ancillary therapies for the management of Parkinson's disease; Index.

'In summary, this is an excellent book on the most current scientific knowledge we have so far on Parkinson's disease, including surgical management, results from clinical trials, and the most current and future treatment options available with drugs.' Nano Khilnani, Biz India Online News (www.bizindia.net)

Nestor Galvez-Jimenez MD is Professor of Medicine (Neurology-Florida) at Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, and Pauline M. Braathen Endowed Chair, Director of the Neurological Center, Chief of the Movement Disorders Unit, and Chairman of the Department of Neurology, at Cleveland Clinic Florida, Weston, FL, USA. Hubert H. Fernandez is Head of the Division of Movement Disorders at the Department of Neurology, Cleveland Clinic, Cleveland, OH, USA. Alberto J. Espay is Associate Professor of Neurology, Director, and Endowed Chair at the James J. and Joan A. Gardner Center for Parkinson's Disease and Movement Disorders, University of Cincinnati Academic Health Center, Cincinnati, OH, USA. Susan H. Fox is Associate Professor of Neurology at the University of Toronto, Associate Director of the Movement Disorders Clinic at Toronto Western Hospital, and Staff Neurologist in the Division of Neurology, Department of Medicine, University Health Network, Toronto, Canada.

• Part I. The Pharmacological Basis for Parkinson's Disease Treatment: 1. The pharmacological basis of Parkinson's disease therapy: an overview; 2. Anticholinergic agents in the management of Parkinson's disease; 3. Amantadine and antiglutamatergic drugs in the management of Parkinson's disease; 4. Monoamine oxidase inhibitors in the management of Parkinson's disease; 5. Oral dopamine agonists in the anagement of Parkinson's disease; 6. Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson's disease; 7. Oral and infusion levodopa therapy in the management of Parkinson's disease; 8. Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease; 9. Experimental pharmacological agents in the management of Parkinson's disease; Part II. Management of Non-Motor Symptoms of Parkinson's Disease: 10. Management of autonomic dysfunction in Parkinson's disease; 11. Management of cognitive impairment in Parkinson's disease; 12. A neurobehavioralist approach to the management of cognitive impairment in Parkinson's disease; 13. Management of disease-related behavioral disturbances in Parkinson's disease; 14. Management of treatment-related behavioral disturbances in Parkinson's disease; 15. Management of sleep disorders in Parkinson's disease; 16. Management of pain and euromuscular complications in Parkinson's disease; Part III. Surgical Management of Parkinson's Disease: 17. Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease; 18. Deep brain stimulation of the globus pallidus internus in the management of Parkinson's disease; 19. Deep brain stimulation of the subthalamic nucleus in the management of Parkinson's disease; 20. Deep brain stimulation of the thalamic ventral intermediate nucleus in the management of Parkinson's disease; 21. Emerging targets and other stimulation-related procedures in the management of Parkinson's disease; Part IV. Clinical Trials in Parkinson's Disease: Lessons, Controversies and Challenges: 22. Rating scales and clinical outcome measures in the evaluation of patients with Parkinson's disease; 23. Functional imaging markers as outcome measures in clinical trials for Parkinson's disease; 24. Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease; 25. Lessons learned: neuroprotective trials in Parkinson's disease; 26. Lessons learned: symptomatic trials in early Parkinson's disease; 27. Controversy: GPi vs STN deep brain stimulation in the management of Parkinson's disease; 28. Controversy: ablative surgery vs deep brain stimulation in the management of Parkinson's disease; 29. Controversy: mid-stage vs advanced stage deep brain stimulation in the management of Parkinson's disease; 30. Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease; 31. Lessons and challenges of trials for other non-motor complications of Parkinson's disease; 32. Lessons and challenges of trials involving ancillary therapies for the management of Parkinson's disease; Index.

'In summary, this is an excellent book on the most current scientific knowledge we have so far on Parkinson's disease, including surgical management, results from clinical trials, and the most current and future treatment options available with drugs.' Nano Khilnani, Biz India Online News (www.bizindia.net)

Nestor Galvez-Jimenez MD is Professor of Medicine (Neurology-Florida) at Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, and Pauline M. Braathen Endowed Chair, Director of the Neurological Center, Chief of the Movement Disorders Unit, and Chairman of the Department of Neurology, at Cleveland Clinic Florida, Weston, FL, USA. Hubert H. Fernandez is Head of the Division of Movement Disorders at the Department of Neurology, Cleveland Clinic, Cleveland, OH, USA. Alberto J. Espay is Associate Professor of Neurology, Director, and Endowed Chair at the James J. and Joan A. Gardner Center for Parkinson's Disease and Movement Disorders, University of Cincinnati Academic Health Center, Cincinnati, OH, USA. Susan H. Fox is Associate Professor of Neurology at the University of Toronto, Associate Director of the Movement Disorders Clinic at Toronto Western Hospital, and Staff Neurologist in the Division of Neurology, Department of Medicine, University Health Network, Toronto, Canada.

• Part I. The Pharmacological Basis for Parkinson's Disease Treatment: 1. The pharmacological basis of Parkinson's disease therapy: an overview; 2. Anticholinergic agents in the management of Parkinson's disease; 3. Amantadine and antiglutamatergic drugs in the management of Parkinson's disease; 4. Monoamine oxidase inhibitors in the management of Parkinson's disease; 5. Oral dopamine agonists in the anagement of Parkinson's disease; 6. Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson's disease; 7. Oral and infusion levodopa therapy in the management of Parkinson's disease; 8. Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease; 9. Experimental pharmacological agents in the management of Parkinson's disease; Part II. Management of Non-Motor Symptoms of Parkinson's Disease: 10. Management of autonomic dysfunction in Parkinson's disease; 11. Management of cognitive impairment in Parkinson's disease; 12. A neurobehavioralist approach to the management of cognitive impairment in Parkinson's disease; 13. Management of disease-related behavioral disturbances in Parkinson's disease; 14. Management of treatment-related behavioral disturbances in Parkinson's disease; 15. Management of sleep disorders in Parkinson's disease; 16. Management of pain and euromuscular complications in Parkinson's disease; Part III. Surgical Management of Parkinson's Disease: 17. Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease; 18. Deep brain stimulation of the globus pallidus internus in the management of Parkinson's disease; 19. Deep brain stimulation of the subthalamic nucleus in the management of Parkinson's disease; 20. Deep brain stimulation of the thalamic ventral intermediate nucleus in the management of Parkinson's disease; 21. Emerging targets and other stimulation-related procedures in the management of Parkinson's disease; Part IV. Clinical Trials in Parkinson's Disease: Lessons, Controversies and Challenges: 22. Rating scales and clinical outcome measures in the evaluation of patients with Parkinson's disease; 23. Functional imaging markers as outcome measures in clinical trials for Parkinson's disease; 24. Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease; 25. Lessons learned: neuroprotective trials in Parkinson's disease; 26. Lessons learned: symptomatic trials in early Parkinson's disease; 27. Controversy: GPi vs STN deep brain stimulation in the management of Parkinson's disease; 28. Controversy: ablative surgery vs deep brain stimulation in the management of Parkinson's disease; 29. Controversy: mid-stage vs advanced stage deep brain stimulation in the management of Parkinson's disease; 30. Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease; 31. Lessons and challenges of trials for other non-motor complications of Parkinson's disease; 32. Lessons and challenges of trials involving ancillary therapies for the management of Parkinson's disease; Index.

'In summary, this is an excellent book on the most current scientific knowledge we have so far on Parkinson's disease, including surgical management, results from clinical trials, and the most current and future treatment options available with drugs.' Nano Khilnani, Biz India Online News (www.bizindia.net)